Evaluation of microspheres containing cytokine neutralizing antibodies in endotoxemia

Drug Development and Industrial Pharmacy

Volumn 25, Issue 6, 1999, Pages 727-734

  D'Souza, Martin J ^a   Oettinger, Carl W ^b   Milton, Grace V ^b  

^a MERCER UNIVERSITY   (United States)

^b Dialysis Clinic Inc   (United States)

Author keywords

Albumin microspheres; Cytokines; Endotoxemia; Interleukin 1 beta; Macrophages; Tumor necrosis factor alpha

Indexed keywords

ALBUMIN; ENDOTOXIN; INTERLEUKIN 1BETA; MICROSPHERE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; ENDOTOXEMIA; IMMUNOTHERAPY; LETHALITY; MICROENCAPSULATION; MORTALITY; NONHUMAN; RAT; SURVIVAL RATE;

ANIMALS; ANTIBODIES; CYTOKINES; DRUG INTERACTIONS; ENDOTOXEMIA; HUMANS; INTERLEUKIN-1; MICROSPHERES; RATS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032959094     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-100102232     Document Type: Article

References (29)

1. C. S. Marcus, J. H. Kuperus, J. A. Butler, P. L. Henneman, R. D. Salk, B. Y. Chen, M. R. P. Vivian, and L. M. Yamanaka, Phagocytic labelling of leukocytes with 99m Tc-albumin colloid for nuclear imaging, Nucl. Med. Biol., 15, 673-682 (1988).
2. B. A. Rhodes, I. Zolle, J. W. Buchanan, et al. Radioactive albumin microspheres for studies of the pulmonary circulation, Radiology, 92, 1453-1460 (1969).
3. I. Zolle, B. A. Rhodes, and H. N. Wagner, Preparation of metabolizable radioactive human serum albumin microspheres for studies of the circulation, Int. J. Appl. Radiat. Isot., 21, 155-167 (1970).
4. A. Bender, V. Schafer, A. M. Steffan, C. Royer, J. Kreuter, H. Rubsamen-Waigmann, and H. von Briesen, Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles, Res. Virol., 145, 215-220 (1994).
5. D. A. Gerber, C. W. Oettinger, M. J. D'Souza, G. V. Milton, C. P. Larsen, and T. C. Pearson, Prolongation of murine cardiac allograft survival by microspheres containing TNFα and IL-1β neutralizing antibodies, J. Drug Targeting, 3, 311-315 (1995).
6. H. Sah, R. Toddywala, and Y. W. Chien, Continuous release of proteins from biodegradable microcapsules and in vivo re-evaluation of their potential as a vaccine adjuvant, J. Controlled Release, 35, 137-144 (1995).
7. G. B. Saha, D. H. I. Feiglin, J. K. O'Donnell, R. T. Go, P. M. Karam, and W. Macintyre, Experience with Technetium-99m albumin colloid kit for reticuloendothelial system imaging, Radiopharmacy, 14, 149-151 (1986).
8. P. M. B. Melissen, W. van Vianen, O. Bidjai, M. van Marion, and I. A. J. M. Bakker-Wouddenberg, Free and liposome-encapsulated muramyl tripeptide phosphidyl-ethanolamine (MTPPE) and interferon-γ in experimental infection with Listeria monocytogenes, Biotherapy, 6, 113-124 (1993).
9. S. Hockertz, G. Franke, I. Paulini, and M. L. Lohmann-Matthes, Immunotherapy of murine visceral Leishmaniasis with murine recombinant interferon-γ and MTP-PE encapsulated in liposomes, J. Interferon Res., 11, 177-185 (1991).
10. E. G. Saravolac, B. Kournikakis, L. Gorton, and J. P. Wong, Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ, Antiviral Res., 29, 199-207 (1996).
11. C. A. Dinarello, J. G. Cannon, S. M. Wolf, H. A. Bernheim, B. Beutler, A. Cerami, I. S. Figari, M. A. Palladino, and J. V. O'Connor, Tumor necrosis factor is an endogenous pyrogen and induces production of interleukin 1, J. Exp. Med., 163, 1433 (1986).
12. J. G. Cannon, R. G. Tompkins, J. A. Gelfand, H. R. Michie, G. C. Stanford, J. W. M. van der Meer, S. Endres, G. Lonnemann, J. Corsetti, B. Chernow, D. W. Wilmore, S. M. Wolff, J. F. Burke, and C. A. Dinarello, Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever, J. Infect. Dis., 161, 79 (1990).
13. A. Cerami, Y. Ikeda, N. Le Trang, P. J. Hotez, and B. Beutler, Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin (tumor necrosis factor), Immunol. Lett., 11, 173 (1985).
14. T. E. Emerson, Jr., D. C. Lindsey, G. J. Jesmok, M. L. Duerr, and M. A. Fournel, Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model, Circ. Shock, 38, 75-84 (1992).
15. T. van der Poll, M. Levi, S. J. H. van Deventer, H. ten Carte, B. L. Haagmans, B. J. Beimond, H. R. Buller, C. E. Hack, and J. W. ten Carte, Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory response in experimental endotoxemia in chimpanzees, Blood, 83, 446-451 (1994).
16. K. Ohlsson, P. Bjork, M. Bergenfeldt, R. Hageman, and R. C. Thompson, Interleukin-1 receptor antagonist reduces mortality from endotoxin shock, Nature, 348, 550-552 (1990).
17. G. Wakabayashi, J. A. Gelfand, J. F. Burke, R. C. Thompson, and C. A. Dinarello, A specific receptor antagonist to interleukin1 improves survival after lethal endotoxemia in mice, FASEB J., 5, 338-343 (1991).
18. H. R. Alexander, G. M. Doherty, C. M. Buresh, D. J. Venzon, and J. A. Norton, A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice, J. Exp. Med., 173, 1029-1032 (1991).
19. R. Pourfarzib, D. Gajjar, I. Riadi, J. Oliver, and M. J. D'Souza, Enzyme linked immunosorbent assay for detection of human tumor necrosis factor alpha, Pharm. Res., 10, S-400 (1993).
20. R. Pourfarzib, D. Gajjar, I. Riadi, J. Oliver, and M. J. D'Souza, Enzyme linked immunosorbent assay for detection of human interleukin-1beta, Pharm. Res., 10, S-400 (1993).
21. J. C. Oliver, L. A. Bland, C. W. Oettinger, M. J. Arduino, S. K. McAllister, S. M. Aguero, and M. S. Favero, Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge, Lymphokine Cytokine Res., 12, 115-120 (1993).
22. E. Mattsson, H. Van Dijk, K. Van Kessel, J. Verhoef, A. Fleer, and J. Rollof, Intracellular pathways involved in tumor necrosis factor-α release by human monocytes on stimulation with lipopolysaccharide or staphylococcal peptidoglycan are partly similar, J. Infect. Dis., 173, 212-218 (1996).
23. V. Willeaume, V. Kruys, T. Mijatovic, and G. Huez, Tumor necrosis factor-α production induced by viruses and by lipopolysaccharides in macrophages: Similarities and differences, J. Inflammation, 46, 1-12 (1996).
24. D. G. Hesse, K. J. Tracey, Y. Fong, K. R. Manogue, M. A. Palladino, A. Cerami, G. T. Shires, and S. F. Lowry, Cytokine appearance in human endotoxemia and primate bacteremia, Surg. Gynecol. Obstet., 166, 147-153 (1988).
25. M. G. Netea, W. L. Blok, B.-J. Kullberg, M. Bemelmans, M. T. E. Vogels, W. A. Buurman, and J. W. M. van der Meer, Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice, J. Infect. Dis., 171, 393-399 (1995).
26. D. A. Russell, K. K. Tucker, N. Chinookoswong, R. C. Thompson, and T. Kohno, Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ function, J. Infect. Dis., 171, 1528-1538 (1995).
27. L. D. Saravolatz, J. C. Wherry, C. Spooner, N. Markowitz, R. Allred, D. Remick, M. Fournel, and E. Pennington, Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-α, J. Infect. Dis., 169, 214-217 (1994).
28. M. J. D'Souza and P DeSouza, Site specific microencapsulated drug targeting strategies - liver and gastro-intestinal tract targeting, Adv. Drug Delivery Rev., 17, 247-254 (1995).
29. M. P. de Caestecker, B. A. Telfer, I. V. Hutchinson, and F. W. Ballardie, The detection of intracytoplasmic interleukin-α, interleukin-β and tumor necrosis factor α expression in human monocytes using two colour immunofluorescence flow cytometry, J. Immunol. Meth., 154, 11-20 (1992).